In 2017, olaparib was approved by the FDA as maintenance therapy in platinum-sensitive high-grade ovarian cancer patients irrespective of the BRCA status, based on phase 3 clinical trials that showed longer median progression-free survival compared with placebo, from 5.5 mo to 19.1 mo (Pujade-Lauraine et al. 2017) or from 13.8 to 49.9 mo in patients with germline BRCA1/2 mutations (Table 2; Moore et al. 2018). Here, BRCA1 is linked to ovarian cancer.